Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: Sunitinib, sorafenib, bevacizumab and temsirolimus;Angiogeneseremmers voor de systemische behandeling van gemetastaseerd niercelcarcinoom: Sunitinib, sorafenib, bevacizumab en temsirolimus

Nederlands Tijdschrift voor Geneeskunde

Volumn 152, Issue 7, 2008, Pages 371-375

  De Mulder, P H M ^a   Haanen, J B A G ^b   Sleijfer, S ^c   Kruit, W H J ^c   Gietema, J A ^d   Richel, D J ^e   Groenewegen, G ^f   Voest, E E ^f   Van Den Eertwegh, A J M ^g   Osanto, S ^h   Jansen, R L H ⁱ   Mulders, P F A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; INTERLEUKIN 2; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ANGIOGENESIS; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL TRIAL; DRUG INDICATION; DRUG MEGADOSE; ENZYME INHIBITION; HIGH RISK PATIENT; HUMAN; KIDNEY CARCINOMA; LUNG METASTASIS; PROGNOSIS; PROGRESSION FREE SURVIVAL; SHORT SURVEY; SIGNAL TRANSDUCTION; SYSTEMIC THERAPY; UNSPECIFIED SIDE EFFECT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOTHERAPY; INDOLES; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PYRIDINES; PYRROLES; SIGNAL TRANSDUCTION; SIROLIMUS; TREATMENT OUTCOME;

EID: 39549118351     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (14)

1. Mulders PFA, Brouwers AH, Hulsbergen-van der Kaa CA, Lin ENJTh van, Osanto S, Mulder PHM de. Richtlijn 'Niercelcarcinoom'. Ned Tijdschr Geneeskd. 2008;152:376-80.
2. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005; 353:2477-90.
3. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003;349:427-34.
4. Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet. 2007;370:2103-11.
5. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.
6. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006;295:2516-24.
7. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.
8. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebeis M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. Target Study Group. N Engl J Med. 2007;356:125-34.
9. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R Kapoor A, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007;356:2271-81.
10. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-40.
11. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer Inst. 2007;99:81-3.
12. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res. 2004;10(18 Pt 2):6367S-70S.
13. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-9.
14. Mickisch GH, Garin A, Poppel H van, Prijck L de, Sylvester R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Lancet. 2001;358: 966-70.